Aripiprazole

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Revision as of 21:49, April 27, 2021 by Kmdenmark (talk | contribs) (CS1 error)

Aripiprazole, which is also sold under the brand names abilify and aripiprazol, is an atypical antipsychotic drug and anti-inflammatory drug used for a number of different conditions including:

Theory[edit | edit source]

One hypothesized theory of aripiprazole’s mode of action is that it may work as a biofilm disruptor[2] and affect the gut-brain axis that way.

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Notable studies[edit | edit source]

  • 2012, The role of Antipsychotics in the Management of Fibromyalgia[3] - (Abstract)
  • 2019, Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans[4]
  • 2021, Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole[5]

Blogs[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Aripiprazole". Drugs.com. Retrieved October 4, 2020.
  2. Rajasekharan, Satish Kumar; Lee, Jin-Hyung; Lee, Jintae (October 2019). "Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans". International Journal of Antimicrobial Agents. 54 (4): 518–523. doi:10.1016/j.ijantimicag.2019.05.016. ISSN 1872-7913. PMID 31173863.
  3. Calandre, Elena P.; Rico-Villademoros, Fernando (February 1, 2012). "The Role of Antipsychotics in the Management of Fibromyalgia". CNS Drugs. 26 (2): 135–153. doi:10.2165/11597130-000000000-00000. ISSN 1179-1934.
  4. Rajasekharan, Satish Kumar; Lee, Jin-Hyung; Lee, Jintae (October 2019). "Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans". International Journal of Antimicrobial Agents. 54 (4): 518–523. doi:10.1016/j.ijantimicag.2019.05.016. ISSN 1872-7913. PMID 31173863.
  5. Crosby, L. D.; Kalanidhi, S.; Bonilla, A.; Subramanian, A.; Ballon, J. S.; Bonilla, H. (February 3, 2021). "Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole". J Transl Med. 19 (50). doi:10.1186/s12967-021-02721-9. ISSN 1479-5876.